Scalper1 News
With 2014 already the strongest year for mergers and acquisitions since 2007, the flurry of dealmaking has given shares of some large drugmakers a shot in the arm — or face, in the case of Botox maker Allergan (AGN). But not all offers have been made peacefully. Valeant Pharmaceuticals (VRX) officially announced plans Tuesday to make its $53 billion bid for Allergan a hostile one. Allergan is one of the three pharmaceutical companies on the Big Scalper1 News
Scalper1 News